Advancements in Targeted Drug Delivery Systems: A Review
Keywords:
Drug Delivery, Nanoparticles, Peptide-Mediate Delivery, Drug- TherapiesAbstract
Targeted drug delivery systems have revolutionized the field of medicine by enhancing the efficacy and specificity of drug therapies while minimizing side effects. This review paper aims to provide an overview of the recent advancements in targeted drug delivery systems, discussing various strategies, technologies, and applications. The paper also presents a comprehensive analysis of the challenges and potential future directions in this evolving field.
How to cite this article:
Prasad M, Advancements in Targeted Drug
Delivery Systems: A Review. Int J Adv Res Med
Chem 2023; 5(1): 9-11
References
Torchilin, V. P. Targeted polymeric micelles for delivery of poorly soluble drugs. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2014; 6(5):485- 506.
Chari, R. V. J, Miller, et.al Widdison, W. C. Antibodydrug conjugates: an emerging concept in cancer therapy. Angewandte Chemie International Edition 2014; 53(15): 3796-3827.
Ruoslahti, E, Bhatia, et.al. Targeting of drugs and nanoparticles to tumors. Journal of Cell Biology 2010; 188(6), 759-768.
Peer, D, Karp, et.al Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2007; 2(12); 751-760.
Hrkach, J, Von Hoff, et. alPreclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine 2012; 4(128); 128ra39.
Lammers T, Kiessling, F Hennink, et. al Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release 2016; 161(2): 175-187.
Yhee, J. Y., Yoon, et.al Cancer-targeted MDR-1 siRNA delivery using self-crosslinked glycol chitosan nanoparticles to overcome drug resistance. Journal of Controlled Release 2016; 237: 98-106.
Maeda, H., & Khatami, M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumorselective drug delivery, low therapeutic efficacy and unsustainable costs. Clinical and Translational Medicine 2018; 7(1): 11.
Alshaer, W., & Hillaireau H. Fattal, E. Aptamer-guided siRNA-loaded nanoparticles for cancer therapy: principles, applications and recent advances. European Journal of Pharmaceutics and Biopharmaceutics 2020; 147: 28-41.
Wilczewska, A. Z., & Niemirowicz K. Markiewicz, K. Targeted nanoparticles in cancer therapy. Journal of Nanobiotechnology 2019; 17(1); 1-19.ww
